Funding Announcements

"Our mission is simple: give mid-market organisations an integrated platform that works the way their business works – without the complexity, hidden costs or bolt-ons that often come through alternative providers. BGF’s backing helps us move faster, while staying true to the customer-first philosophy that sets us apart."

"Earlier versions struggled with fast, complex motion, either requiring an excessive number of Gaussians or producing visible artifacts. Our latest release finally solves this: even footage captured at 50fps can now be played back in ultra-smooth slow motion with minimal artifacts, while preserving fine details. This makes 4DGS viable for high-demand use cases like sports and film."

"If you’ve ever bought a house in the UK, you’ll know exactly how painful the conveyancing process can be. Something that should take a matter of days can drag on for months, leaving you unsure when – or even if – you’ll get the keys to your new home. These delays are completely avoidable. We built Conveyd to remove unnecessary back-and-forth, so home buyers get complete purchases in weeks rather than months – in a way that doesn’t make them want to tear their own hair out."

"Everything around us is manufactured, from the mug on your desk to the optical cables carrying our Netflix binges. Everyone talks about the glamorous side of manufacturing: generative design, material discovery, digital twins, but few spend time on the factory floor. The hard part isn’t dreaming things up inside a computer; it’s making them work at scale. Manufacturing still runs on human know-how, the kind that lets someone on the line kick a machine just right, or run a finger over a scratch, and say, ‘that’s thirty-four microns wide.’ We’re using AI to capture and scale that tacit knowledge, so engineers can design things that actually work in the real world. It’s time to manufacture the impossible."

"Refractory epilepsy is a devastating condition causing unpredictable and life-threatening seizures, and affecting millions of patients worldwide. Our novel gene therapy EPY201 delivered directly to the seizure focus has the potential to stop seizures with a single, minimally invasive administration. In doing so, it will change the way refractory epilepsy has been treated for decades. We are proud to have the support of such high calibre investors as we progress into clinical trials."